Iceland· IS-IS/1/12/096/01
Flutiform
A formoterol und fluticason product containing fluticasonum inn própíónat,formoterolum inn fúmarat, registered in Iceland by Mundipharma A/S. The same ATC class is registered in 9 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Formoterol und fluticason is registered in 9 of 19 countries.
Countries holding a registration under ATC R03AK11 (formoterol und fluticason), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 6 of them publish a price we can compare per daily dose
Formoterol und fluticason · ATC R03AK11
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Switzerlandprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Fluticasonum INN própíónat,Formoterolum INN fúmarat
- Manufacturer
- Mundipharma A/S
- Country
- Iceland (IS)
- ATC code
- R03AK11
- ATC class
- Formoterol und Fluticason
- Defined daily dose
- 24 mcg, Inhal
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Formoterol und fluticason in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomFlutiform 125micrograms/dose / 5micrograms/dose inhalerPilsco Ltd
- NetherlandsFlutiform 125 microgram / 5 microgram / dosis aerosol, suspensieEuro Registratie Collectief B.V.
- FinlandFlutiformMundipharma Oy
- IrelandFlutiform 125 microgram/5 microgram per metered dose pressurised inhalation, suspensionMundipharma Pharmaceuticals Limited
- SwedenAbriff 125 mikrogram/5 mikrogram/puff Inhalationsspray, suspensionMundipharma AB
- CzechiaFLUTIFORMMundipharma Gesellschaft m.b.H., Vídeň
- NorwayFlutiformAbacus Medicine A/S
- SpainFLUTIFORM 125 MICROGRAMOS / 5 MICROGRAMOS/ INHALACION SUPSENSION PARA INHALACION EN ENVASE A PRESIONMundipharma Pharmaceuticals S.L.
Authorised across Europe · EMA
The same active substance is authorised in 21 EEA countries. Names it is sold under:
- Austria · Flutiform
- Belgium · Flutiform
- Bulgaria · Flutiform
- Cyprus · Flutiform
- Czechia · Flutiform
- Germany · Flutiform
- Denmark · Flutiform
- Spain · Flutiform
- Finland · Flutiform
- France · Flutiform
- United Kingdom (Northern Ireland) · Affera, Flutiform
- Croatia · Flutiform
- Ireland · Flutiform
- Italy · Abriff, Flutiformo
- Luxembourg · Flutiform
- Netherlands · Flutiform
- Norway · Flutiform
- Portugal · Flutiform
- Sweden · Abriff, Flutiform
- Slovenia · Flutiform
- Slovakia · Flutiform
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4051ad14-d055-4bfc-9e2e-61240a40a823 GET /v1/drugs/4051ad14-d055-4bfc-9e2e-61240a40a823?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Innúðalyf, dreifa",
"source": "lyfjastofnun",
"atc_raw": "R03AK11",
"marketed": true,
"strength": "50 míkróg/5 míkróg",
"ma_number": "IS/1/12/096/01",
"substance": "Fluticasonum INN própíónat,Formoterolum INN fúmarat",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt",
"ma_issued_serial": "41173"
}See everything about formoterol und fluticason.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.